摘要
目的:研究急性髓系白血病(acute myeloid leukemia,AML)患者中高尔基体Raf激酶陷阱蛋白(Raf kinase trapping to Golgi,RKTG)蛋白的表达,探讨RKTG蛋白在AML中的意义。方法:以64例AML患者骨髓单个核细胞为研究对象,采用免疫组织化学染色法和Western Blot法分析RKTG蛋白的表达。结果:免疫组织化学染色检测显示阳性率:RKTG蛋白在初诊组的表达率为5. 13%,完全缓解组为68. 00%,对照组为75. 00%。Western Blot法检测显示阳性率:初诊组为25. 64%,完全缓解组为92%,对照组为90. 0%;初诊组与对照组、完全缓解组表达率相比较,有统计学差异(P <0. 05);完全缓解组与对照组比较无统计学差异(P> 0. 05)。初诊组AML不同亚型中,RKTG蛋白在M3型中的表达较非M3型中表达水平未见明显差异(P>0. 05)。结论:RKTG蛋白在初诊AML组中的表达较对照组明显减低或缺失,提示AML的发病与RKTG蛋白的表达存在关联。完全缓解组中RKTG蛋白的表达恢复,与对照组相比没有统计学差异,提示RKTG蛋白的表达可能与AML治疗预后相关。
Objective:To study the expression of RKTG protein in patients with acute myeloid leukemia(AML) and to explore the significance of RKTG protein in AML.Methods:In 64 patients with AML bone marrow mononuclear cells as the research object,using immunohistochemical staining method and Western Blot method analyzed RKTG protein expression.Results:Positive results in immunohistochemical staining:RKTG protein expression rate was 5.13% in the primary treatment group,complete remission group was 68.00%,the control group was 75.00%.The positive results in Western Blot:25.64% in the primary treatment group,92% in the complete remission group and 90.0% in the control group.The data of the primary treatment group compared with the control group and the complete remission group were statistically significant (P〈0.05).There was no statistical significance between the CR group and the control group(P〉0.05).The expression of RKTG protein in different subtypes of AML in the primary treatment group was not significantly different from that in the non-M3 group(P〉0.05).Conclusion:The expression of RKTG protein in the primary treatment AML and CR group was significantly reduced or absent comparaed with the control group,suggesting that the pathogenesis of AML was associated with the expression of RKTG protein.The expression of RKTG protein in the complete remission group was restored,and there was no statistical difference compared with the control group,suggesting that the expression of RKTG protein may be related to the prognosis of AML.
作者
王晓欧
邓娜
徐赢东
刘琳
廖子龙
樊华
Wang Xiaoou;Deng Na;Xu Yingdong;Liu Lin;Liao Zilong;Fan Hua(Fourth Hospital Affiliated of China Medical University,Liaoning Shenyang 110032,China;First Hospital Affiliated of China Medical University,Liaoning Shenyang 110002,China;Enshi Central Hospital,Hubei Enshi 445000,China)
出处
《现代肿瘤医学》
CAS
2018年第23期3849-3853,共5页
Journal of Modern Oncology
基金
辽宁省教育厅科学研究项目(编号:L2015569)